Macquarie is a joke., page-29

First 29 Last

Share
Profile

Follow
shades2

2,768 Posts.

10

11/08/16

10:26

Post #: 18492840
Share

Originally posted by Ravenhaller ↑

Regardless of Macquarie's position, their analysis/article has done the job it was intended to do, and volatility will continue to be ultra high for at least a few more trading sessions. Reality is I expect that article will likely reach a greater audience, than posting here on hot Copper.

Frustrating... frustrating that Macquarie can publish/elicit an opinion on lithium/GXY when it's glaringly obvious it's the writer hasn't read a single of our announcements in the last six months... frustrating when a non-analyst like me can easily spot flaws in the broader information / data / numbers... frustrating that this guy works for a reputable bank, is an analyst for a living, yet his finger couldn't be further from the pulse... frustrating that he has a soapbox to preach from, and no accountability for the damage he creates.

Urrgh.

At the end of the day, the fundamentals haven't changed. Mt Cattlin is up and running. We have customers. We have exceptionally low levels of debt. We have two major assets that are easily developed. And the world - slowly but surely - is moving away from the fossil fuel paradigm.

Expand

Things will get interesting as shipments are made, and money flows in and P/E ratio becomes a thing..

What will Macquarie's nay-sayers do then?

Last edited by shades2: 11/08/16

GXY Price at posting: 41.3¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

AUG

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

RNU

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

TX3

Canadian fieldwork yields multiple pegmatites for Trinex

TLX

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug